Cleveland Clinic Tall Rounds®: Caring for Your Patients with ATTR
Treating Confirmed ATTR
Release date: April 30, 2024
Expiration date: April 29, 2026
Estimated Time of Completion: 1 hour
Description
Early diagnosis and intervention for transthyretin amyloidosis (ATTR) is critical, yet does not occur, typically as a consequence of the rarity and heterogeneity of the disease and limited awareness on the part of clinicians. Therapeutic options are limited, but there are new and emerging agents and emerging indications with which clinicians may not be familiar. Access to specialized care centers is limited for many patients, leading to suboptimal management and disease monitoring. This education fills a significant need for healthcare team education to ensure all patients benefit from best-practices in recognizing, diagnosing, and managing amyloidosis. Learn More about the Cleveland Clinic Amyloidosis Center
Session Agenda
Moderator Introduction: Mazen Hanna, MD
Case Presentation: Arianne Clare C. Agdamag, MD
Management of Cardiac Involvement: Preethi William, MD
Treatment of ATTR Cardiac Amyloidosis
Stabilizer Therapy: Trejeeve Martyn, MD, MSc
Silencer Therapy: Andres Carmona Rubio, MD
Antibody Therapy: Mazen Hanna, MD
Treatment of AL Amyloidosis: Jack Khouri, MD
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are Free of commercial bias.
The following faculty has indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest: Kathleen Breznai, Jeanna Sigmund, MSN, Arianne Clare Agdamag, MD, Andres E Carmona Rubio, MD, Preethi William, MBBS
The following faculty has indicated that they may have a relationship, which in the context of their presentation(s) could be perceived as a potential conflict of interest: Eric E Roselli, MD: Artivion - Consulting, Teaching and Speaking. Cook Medical - Teaching and Speaking. Cryolife, Inc. - Consulting. Terumo - Teaching and Speaking. W.L. Gore & Associates - Consulting. Medtronic - Consulting. Edwards Lifesciences - Teaching and Speaking. Abbott - Teaching and Speaking. LivaNova, PLC - Consulting, Teaching and Speaking. Mazen Hanna, MD: Pfizer - Advisor or review panel participant. Alexion - Advisor or review panel participant. Alnylam - Advisor or review panel participant. Akcea Therapeutics, Inc. - Advisor or review panel participant. Eidos Therapeutics - Advisor or review panel participant. Michael Trejeeve Martyn, MD: Recora Health - Consulting. Synkopi inc. - Consulting. Synkopi Inc. - Consulting. Recora Health - Consulting. Astra Zeneca - Research. Astra Zeneca - Research. Ionis Pharmaceuticals - Research. Ionis Pharmaceuticals -Research. Akcea Therapeutics, Inc. - Research. The Clinic by Cleveland Clinic - Consulting. The Clinic by Cleveland Clinic - Consulting. Fire1 - Consulting. Apricity Robotics - Consulting. Boehringer Ingelheim - Consulting. Jack Khouri, MD: GPCR Therapeutics - Teaching and Speaking, Research. Janssen Pharmaceuticals, Inc. - Consulting, Advisor or review panel participant.
Acknowledgment
The Cleveland Clinic Center for Continuing Education acknowledges educational grants for partial support of this activity from:
Alexion Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
AstraZeneca Pharmaceuticals
Please take before viewing this webcast
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, The France Foundation, and Cleveland Clinic’s Heart, Vascular and Thoracic Institute.
For further information about this activity, contact Katie Breznai at [email protected]